The PMDA inspection closed with no critical or major observations
Pharma company Lupin today announced the completion of the Good Manufacturing Practices (GMP) inspection of its Mandideep facility (Unit-2), by the Pharmaceutical and Medical Devices Agency (PMDA), Japan. The inspection was conducted between May 14, 2019 and May 17, 2019.
The PMDA inspection closed with no critical or major observations.
- Advertisement -
Comments are closed.